HOME >> MEDICINE >> NEWS
Preclinical results of Geovax's AIDS vaccines demonstrate potential to protect against disease

GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology company, today reported successful results from a preclinical trial using GeoVax's vaccines for the therapeutic treatment and prevention of Acquired Immunodeficiency Disease Syndrome ("AIDS") in non-human primates. The data demonstrate the effectiveness of GeoVax's DNA/MVA vaccines in controlling the Simian ("SIV") AIDS virus through immune responses raised by the vaccines. These promising results have resulted in preliminary plans to conduct human therapeutic studies utilizing GeoVax's vaccines.

In this trial, two monkeys were infected with the SIV AIDS virus and then placed on drug therapy. Thereafter, once early drug therapy had temporarily reduced virus levels, the monkeys were vaccinated with the SIV version of GeoVax's DNA/MVA vaccines. Six weeks after vaccination, drug treatment was discontinued. The SIV virus levels temporarily rose in the vaccinated individuals, but were later "controlled" (reduced to much lower levels) by immune responses raised by the vaccines.

The reduction of virus levels in the blood stream of these AIDS virus-infected non-human primates has continued for more than a year to date. Vaccination with the GeoVax DNA/MVA vaccines has curtailed the development of AIDS and its associated debilitating effects, resulting in healthy, asymptomatic individuals. The monkeys have gained weight and have not required any additional drug therapy.

"The results of this trial demonstrate the long-term promise of our vaccines in treating HIV-AIDS," said Don Hildebrand, CEO of GeoVax Labs. "Our preclinical trials, coupled with encouraging data from two ongoing human trials, help validate the science behind our vaccines and provide the impetus for accelerating the planning of Phase II human trials for our preventive vaccines."

The ability to vaccinate those already infected with the AIDS virus, thereby inhibiting the virus' progressive and de
'"/>

Contact: Melanie Nimrodi
mnimrodi@mww.com
312-546-3508
Financial Relations Board
6-Feb-2007


Page: 1 2

Related medicine news :

1. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
2. GSKs Pazopanib shows positive results in patients with advanced renal cell carcinoma
3. GSKs Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
4. Targeted, oral agent Enzastaurin shows favorable results
5. Childhood obesity intervention shows promising results
6. Alpharma presents positive pharmacokinetic study results
7. UCSF brain tumor vaccine trial shows promising results
8. The eyes have it -- Autism research yields surprising results
9. ACP: Residency match results for internal medicine underscore need to redesign primary care
10. Positive results more likely from industry-funded breast cancer trials
11. Leading advocates express support for microbicide research, despite disappointing trial results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... Textile ... Responsible Wool Standard (RWS) for public stakeholder review. The stakeholder review is an important ... it meets its goals and delivers value to the wool industry., The RWS is ...
(Date:5/5/2016)... ... 05, 2016 , ... TLC Laser Eye Centers announced today that it has ... will now be called “Gordon Schanzlin New Vision Institute, a TLC Laser Eye Center.” ... facility to ensure that patients continue to receive the highest quality of care. In ...
(Date:5/5/2016)... (PRWEB) , ... May 05, ... ... and hands-on exercises, the Wharton Seminars for Business Journalists , led ... understanding of key business and economic issues.  This one-day program at the ...
(Date:5/5/2016)... ... May 05, 2016 , ... Every year 220 Mississippi kids ... of these children. The wishes provide hope and motivation through positive experiences ... Make-A-Wish Mississippi, Brent Wilson said, “In 2016, the organization will grant 50% of ...
(Date:5/5/2016)... ... 2016 , ... A recent survey by the Midwest Business Group on ... understand and use the free preventive care benefits available to them as part of ... large, self-insured public and private employers, MBGH found that only 10% of large employers ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocythemia Market and ... to their offering.       ... ,The latest research Europe Thrombocythemia Market ... provides comprehensive insights into Thrombocythemia pipeline ...
(Date:5/4/2016)... New York , May 4, 2016 ... by Transparency Market Research entitled "Brain Computer Interface Market - ... 2016 - 2024," the  global brain computer interface (BCI) market ... by 2024. The market is estimated to expand at ... from 2016 to 2024. A BCI device ...
(Date:5/4/2016)... May 4, 2016 In ... a series of free workshops across ... requirements for Good Distribution Practices (GDP). Good ... ensures that products are consistently stored, transported and handled ... (MA) or product specification. Only a few years ago, ...
Breaking Medicine Technology:
Cached News: